| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
BASEL—With a price tag of $272.5 million, Roche has expanded its share of the research genomics market with a definitive agreement to acquire NimbleGen Systems, a high-density microarray specialist based in Madison, Wisc. The portfolio is expected to complement Roche's LightCycler PCR technology, as well as its recently acquired 454 Life Sciences high-throughput sequencing platform.
 
In recent years, the global market for microarray technologies has hovered around $0.5 billion and has historically lagged behind other gene expression technologies because of issues around system interoperability and data inconsistency. The move from homebrew to commercial systems, however, as well as the focus by companies to deal with these problems, has improved the situation.
 
With its acquisition, NimbleGen will become a fully integrated part of Roche Applied Science and will continue to develop new technologies, while leveraging Roche's infrastructure for product development and marketing. Roche expects to retain NimbleGen's 140 employees and operations in Madison, Reykjavik, and Waldkraiburg, Germany. The deal is expected to close in Q3 2007.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A doctor wearing blue gloves and a white lab coat with a stethoscope around their neck holds a rendering of a digestive system on a glass pane with a swirled blue background.

Connecting the gut and liver to enhance drug development

Explore how a dual-organ microphysiological system connects human gut and liver tissue to bridge gaps in predicting how drugs behave in the body.
A syringe draws liquid from a glass vial, with several glass ampoules reflected on a glossy surface in the background

Turning up the heat: thermal analysis for biotherapeutics

Explore essential thermal stability techniques to ensure the safety, quality, and efficacy of biologic drugs.
A 3D-rendered image of a pink and white twisted RNA strand floating against a green, blurred cellular background.

Cutting the time and cost out of plasmid generation

Discover a hassle-free path to obtaining long, complex plasmid DNA.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue